Medical/Pharmaceuticals

CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China

* CBC Group and Mubadala acquire UCB's mature neurology and allergy business inChina for US$680 million. * New company is named NeuroGen Pharma, led by an experienced management team with a strong track record in the biopharma industry. * Strategic acquisition under CBC's buyout strategy exp...

2024-11-30 09:00 6451

BGM Group Ltd Pioneers Innovation in AI Technology, Fostering Holistic Integration of Healthcare and Insurtech

CHENGDU, China, Nov. 29, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), a leading global pharmaceutical enterprise, today announced its acquisition of the intelligent platform of AIX Inc. (NASDAQ: AIFU) ("AIX") valued at1 billion RMB (approximately $140 million). The ...

2024-11-29 23:58 5958

MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China

SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of its Phase III clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for the treatment of adult patients with complex sk...

2024-11-29 22:00 3645

Minghui Pharmaceutical Announces Positive Topline Results from Phase Ⅲ Trial of MH004 (Tofacitinib Etocomil) Ointment in Mild to Moderate Atopic Dermatitis

SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced positive topline results from its phase Ⅲ trial of MH004 (tofacitinib etocomil) ointment 1.0%, a twic...

2024-11-29 20:31 3671

"Are your Hands & Feet trying to tell you something?" - Ask leading Health Experts

* Do you feel numbness, pain, tingling or pins and needles in your hands and feet? * 8 out of 10 patients with Peripheral Neuropathy don't listen to what their nerves are telling them and go undiagnosed leading to worsening of symptoms. MANILA, Philippines, Nov. 29, 2024 /PRNewswire/ -- As pa...

2024-11-29 13:30 2423

Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference

HONG KONG, Nov. 28, 2024 /PRNewswire/ --  Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 7th Annual Evercore HealthCONx Conference and Citi 2024 Global Healthcare Conference, both taking place inMiami. Akeso will participate in a firesid...

2024-11-29 10:23 1977

Borsch Med Partners with Unity Pharmacies to Help Elderly Access Zeria Chondroitin-based Joint Health Supplements in Support of Healthy Ageing in Singapore

SINGAPORE, Nov. 29, 2024 /PRNewswire/ -- Leading health and nutrition company, Borsch Med Pte Ltd (Borch Med) has announced that Zeria chrondroitin-based joint health supplements are now available at selected Unity pharmacies in Singapore. The enhanced distribution network of the Japanese-made sup...

2024-11-29 10:00 2473

Microbio Appoints Paul Brennan as Chair of the Board

BRISBANE, Australia, Nov. 29, 2024 /PRNewswire/ -- Microbio Ltd, the Australian pathogen diagnostics company specialising in innovative molecular diagnostic solutions, has appointedPaul Brennan as Chair of the Board, effective 2nd December 2024. Paul brings extensive global experience as a Non-E...

2024-11-29 06:30 2750

Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific...

2024-11-28 21:30 4496

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecifi...

2024-11-28 21:06 4300

First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

MELBOURNE, Australia, Nov. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma) today announce that a first patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron ...

2024-11-28 17:22 2972

New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List

ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the new indication...

2024-11-28 16:59 3460

Own Your Story with AwarerHOME™

Malaysia's HIV Oral Self-Test for Accessible and Confident Testing KUALA LUMPUR, Malaysia, Nov. 28, 2024 /PRNewswire/ -- Say hello to confidence and control with AwarerHOME™,Malaysia's first homegrown HIV Oral Self-Test. This accessible, no-mess, no-fuss solution offers something even more impor...

2024-11-28 16:34 2644

Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List

SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has been included in the...

2024-11-28 13:43 2859

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hema...

2024-11-28 13:04 3071

Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List

SAN FRANCISCO and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-11-28 12:07 4175

Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab

HONG KONG, Nov. 27, 2024 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce that two of its independently developed, globally pioneering bispecific antibody drugs—cadonilimab Injection (PD-1/CTLA-4 bispecific antibody) and ivonescimab Injection (PD-1/VEGF bi...

2024-11-28 11:58 2573

Newbase Launches 'Medicrew', a VR Medical Training Platform to Accelerate Global Market Expansion

Participation in IMSH 2025 to Showcase Innovations in Medical Education SEOUL, South Korea, Nov. 28, 2024 /PRNewswire/ -- Newbase , a leader in metaverse-based medical education platforms, announced on the 28th the launch of its new product, 'Medicrew', a platform des...

2024-11-28 09:00 2576

Lunit Inks Partnership with Salud Digna to Advance AI in Medical Imaging

* AI-powered chest X-ray and mammography analysis solutions to be deployed across one ofMexico's largest healthcare networks SEOUL, South Korea, Nov. 27, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announc...

2024-11-27 22:00 2616

Prenetics Announces Third Quarter 2024 Financial Results

Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 /P...

2024-11-27 21:30 3777
1 ... 148149150151152153154 ... 646